Webinar | July 26, 2023

How To Bring Your LNP Formulation To Clinical/Commercial Manufacturing Via CTDMO Services

Covid-19 vaccines have demonstrated the clinical potential of mRNA-Lipid Nanoparticle formulations. To enable the development of next-generation lipid-based drug delivery systems, expertise and manufacturing capabilities are critical. Relying on more than 20 years of experience in GMP lipid/LNP manufacturing, MilliporeSigma aims to support pioneers in nucleic acid modalities to bring life-changing medicines from preclinical to commercial manufacturing.

access the Webinar!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Outsourced Pharma

Please tell us more about you so that we can customize our newsletters to your specific interests:

What topics interest you? (Check all that apply.)

MilliporeSigma